Acadia Pharmaceuticals Inc (ACAD)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Malattie rare – Dal CHMP parere positivo per trofinetide per il trattamento della sindrome di Rett

-- La decisione della Commissione europea è prevista nei prossimi mesi -- Se approvato, trofinetide sarebbe il primo trattamento dei sintomi...

DAYBU® (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen

– Die Entscheidung der Europäischen Kommission wird in den kommenden Monaten erwartet. – Im Falle einer Zulassung wird DAYBU® die erste...

DAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett

-- Une décision de la Commission européenne attendue dans les mois à venir -- Si approbation, DAYBU® deviendra le premier traitement du syndrome...

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

-- European Commission decision expected in the coming months -- If approved, DAYBU® would become the first treatment for neurobehavioral...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report